Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

STEFANO VELLA

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

HIV-1
HIV

Procedures

Concepts & Ideas

Viral Load

Physiology

Geographic Areas

Europe

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Palmisano Lucia; Giuliano M; Galluzzo C M; Amici R; Andreotti M; Weimer L E; Pirillo M F; Fragola V; Bucciardini R; Vella S
The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.
Andreotti Mauro; Galluzzo Clementina M; Guidotti Giovanni; Germano Paola; Altan Annamaria Doro; Pirillo Maria Franca; Marazzi Maria Cristina; Vella Stefano; Palombi Leonardo; Giuliano Marina
Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique.
Palmisano Lucia; Giuliano Marina; Bucciardini Raffaella; Andreotti Mauro; Fragola Vincenzo; Pirillo Maria F; Weimer Liliana E; Mancini Maria G; Vella Stefano
Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of STEFANO VELLA (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Palmisano Lucia; Giuliano M; Galluzzo C M; Amici R; Andreotti M; Weimer L E; Pirillo M F; Fragola V; Bucciardini R; Vella S
The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.
HIV medicine 2009;10(8):477-81.
2009: Andreotti Mauro; Galluzzo Clementina M; Guidotti Giovanni; Germano Paola; Altan Annamaria Doro; Pirillo Maria Franca; Marazzi Maria Cristina; Vella Stefano; Palombi Leonardo; Giuliano Marina
Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique.
AIDS research and human retroviruses 2009;25(7):707-11.
2009: Palmisano Lucia; Giuliano Marina; Bucciardini Raffaella; Andreotti Mauro; Fragola Vincenzo; Pirillo Maria F; Weimer Liliana E; Mancini Maria G; Vella Stefano
Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions.
Journal of medical microbiology 2009;58(Pt 1):121-4.
2008: Floridia Marco; Giuliano Marina; Palmisano Lucia; Vella Stefano
Gender differences in the treatment of HIV infection.
Pharmacological research : the official journal of the Italian Pharmacological Society 2008;58(3-4):173-82.
2008: Baroncelli Silvia; Ricci Elisabetta; Andreotti Mauro; Guidotti Giovanni; Germano Paola; Marazzi Maria Cristina; Vella Stefano; Palombi Leonardo; De Rossi Anita; Giuliano Marina
Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters.
AIDS (London, England) 2008;22(12):1515-7.
2008: Palmisano Lucia; Giuliano Marina; Chiarotti Flavia; Zanchetta Marisa; Andreotti Mauro; Pirillo Maria F; Riva Elisabetta; Antonelli Guido; De Rossi Anita; Vella Stefano
Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2008;48(1):68-71.
2008: Baroncelli Silvia; Andreotti Mauro; Guidotti Giovanni; Pirillo Maria F; Ceffa Susanna; Mancini Maria Grazia; Germano Paola; Marazzi Maria Cristina; Vella Stefano; Palombi Leonardo; Giuliano Marina
Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique.
Journal of acquired immune deficiency syndromes (1999) 2008;47(5):647-9.
2007: Pirillo Maria F; Bassani Luciana; Germinario Elena A P; Mancini Maria Grazia; Vyankandondera Joseph; Okong Pius; Vella Stefano; Giuliano Marina
Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda.
Journal of medical virology 2007;79(12):1797-801.
2007: Galluzzo Clementina M; Germinario Elena A P; Bassani Luciana; Mancini Maria Grazia; Okong Pius; Vyankandondera Joseph; Vella Stefano; Giuliano Marina
Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda.
AIDS research and human retroviruses 2007;23(11):1449-51.
2007: Andreotti Mauro; Guidotti Giovanni; Galluzzo Clementina M; Mancinelli Sandro; Germano Paola; Pirillo Maria F; Marazzi Maria Cristina; Vella Stefano; Palombi Leonardo; Giuliano Marina
Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention.
AIDS (London, England) 2007;21(17):2360-2.
2007: Malorni Walter; Campesi Ilaria; Straface Elisabetta; Vella Stefano; Franconi Flavia
Redox features of the cell: a gender perspective.
Antioxidants & redox signaling 2007;9(11):1779-801.
2007: Nicastri Emanuele; Leone Sebastiano; Angeletti Claudio; Palmisano Lucia; Sarmati Loredana; Chiesi Antonio; Geraci Andrea; Vella Stefano; Narciso Pasquale; Corpolongo Angela; Andreoni Massimo
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.
The Journal of antimicrobial chemotherapy 2007;60(4):724-32.
2007: Palmisano Lucia; Giuliano Marina; Bucciardini Raffaella; Fragola Vincenzo; Andreotti Mauro; Galluzzo Clementina; Pirillo Maria F; Weimer Liliana E; Arcieri Romano; Germinario Elena A P; Amici Roberta; Mancini Maria Grazia; Monforte Antonella d'Arminio; Castelli Francesco; Caramello Pietro; Vella Stefano;
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.
Journal of acquired immune deficiency syndromes (1999) 2007;46(1):39-47.
2007: d'Ettorre Gabriella; Zaffiri Lorenzo; Ceccarelli Giancarlo; Andreotti Mauro; Massetti Anna Paola; Vella Stefano; Mastroianni Claudio M; Vullo Vincenzo
Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
HIV clinical trials 2007;8(3):182-8.
2007: Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips A N; Lundgren J D;
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
HIV medicine 2007;8(2):96-104.
2007: Giuliano Marina; Guidotti Giovanni; Andreotti Mauro; Pirillo Maria F; Villani Paola; Liotta Giuseppe; Marazzi Maria Cristina; Mancini Maria Grazia; Cusato Maria; Germano Paola; Loureiro Sandra; Ceffa Susanna; Regazzi Mario; Vella Stefano; Palombi Leonardo
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Journal of acquired immune deficiency syndromes (1999) 2007;44(3):286-91.
2007: Balestrieri Emanuela; Grelli Sandro; Matteucci Claudia; Minutolo Antonella; d'Ettorre Gabriella; Di Sora Fiorella; Montella Francesco; Vullo Vincenzo; Vella Stefano; Favalli Cartesio; Macchi Beatrice; Mastino Antonio
Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy.
Journal of medical virology 2007;79(2):111-7.
2007: Giuliano Marina; Vella Stefano
Inequalities in health: access to treatment for HIV/AIDS.
Annali dell'Istituto superiore di sanità 2007;43(4):313-6.
2006: Grelli Sandro; Balestrieri Emanuela; Matteucci Claudia; Minutolo Antonella; D'Ettorre Gabriella; Lauria Filippo; Montella Francesco; Vullo Vincenzo; Vella Stefano; Favalli Cartesio; Mastino Antonio; Macchi Beatrice
Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy.
Annals of the New York Academy of Sciences 2006;1090():130-7.
2006: Bona Roberta; Andreotti Mauro; Buffa Viviana; Leone Pasqualina; Galluzzo Clementina Maria; Amici Roberta; Palmisano Lucia; Mancini Maria Grazia; Michelini Zuleika; Di Santo Roberto; Costi Roberta; Roux Alessandra; Pommier Yves; Marchand Christophe; Vella Stefano; Cara Andrea
Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.
Antimicrobial agents and chemotherapy 2006;50(10):3407-17.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):827-43.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2006;296(7):827-43.
2006: Giuliano Marina; Galluzzo Clementina M; Germinario Elena A P; Amici Roberta; Bassani Luciana; Dehò Lorenzo; Vyankandondera Joseph; Mmiro Francis; Okong Pius; Vella Stefano
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Journal of acquired immune deficiency syndromes (1999) 2006;42(1):131-3.
2006: Bucciardini R; Murri R; Guarinieri M; Starace F; Martini M; Vatrella A; Cafaro L; Fantoni M; Grisetti R; Monforte A d'Arminio; Fragola V; Arcieri R; Del Borgo C; Tramarin A; Massella M; Lorenzetti D; Vella S
ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2006;15(3):377-90.
2006: d'Ettorre Gabriella; Andreotti Mauro; Carnevalini Martina; Andreoni Carolina; Zaffiri Lorenzo; Vullo Vincenzo; Vella Stefano; Mastroianni Claudio M
Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients.
Immunology letters 2006;103(2):192-5.
2006: Panei Pietro; Knellwolf Anne-Laure; Arcieri Romano; Vella Stefano
Absence of unfavorable effect of atomoxetine on growth in pediatric patients is still not demonstrated.
Pediatrics 2006;117(2):587-8; author reply 588.
2006: Bannister Wendy P; Ruiz Lidia; Loveday Clive; Vella Stefano; Zilmer Kai; Kjaer Jesper; Knysz Brygida; Phillips Andrew N; Mocroft Amanda;
HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Antiviral therapy 2006;11(6):707-15.
2005: Sarmati Loredana; Parisi Saverio Giuseppe; Nicastri Emanuele; d'Ettorre Gabriella; Palmisano Lucia; Andreotti Mauro; Andreoni Carolina; Giuliano Marina; Gatti Francesca; Boldrin Caterina; Palù Giorgio; Vullo Vincenzo; Vella Stefano; Andreoni Massimo
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
Journal of clinical microbiology 2005;43(12):6183-5.
2005: Palmisano Lucia; Giuliano Marina; Nicastri Emanuele; Pirillo Maria Franca; Andreotti Mauro; Galluzzo Clementina M; Bucciardini Raffaella; Fragola Vincenzo; Andreoni Massimo; Vella Stefano
Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.
AIDS (London, England) 2005;19(16):1843-7.
2005: Vella Stefano; Palmisano Lucia
The global status of resistance to antiretroviral drugs.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41 Suppl 4():S239-46.
2005: Nicastri Emanuele; Chiesi Antonio; Angeletti Claudio; Sarmati Loredana; Palmisano Lucia; Geraci Andrea; Andreoni Massimo; Vella Stefano;
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.
Journal of medical virology 2005;76(2):153-60.
2005: Konopnicki Deborah; Mocroft Amanda; de Wit S; Antunes Francisco; Ledergerber Bruno; Katlama Christine; Zilmer K; Vella Stefano; Kirk Ole; Lundgren Jens D;
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS (London, England) 2005;19(6):593-601.
2005: Nicastri Emanuele; Angeletti Claudio; Palmisano Lucia; Sarmati Loredana; Chiesi Antonio; Geraci Andrea; Andreoni Massimo; Vella Stefano;
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy.
AIDS (London, England) 2005;19(6):577-83.
2005: Magoni Michele; Bassani Luciana; Okong Pius; Kituuka Praxedes; Germinario Elena P; Giuliano Marina; Vella Stefano
Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda.
AIDS (London, England) 2005;19(4):433-7.
2004: Vandamme A M; Sönnerborg A; Ait-Khaled M; Albert J; Asjo B; Bacheler L; Banhegyi D; Boucher C; Brun-Vézinet F; Camacho R; Clevenbergh P; Clumeck N; Dedes N; De Luca A; Doerr H W; Faudon J L; Gatti G; Gerstoft J; Hall W W; Hatzakis A; Hellmann N; Horban A; Lundgren J D; Kempf D; Miller M; Miller V; Myers T W; Nielsen C; Opravil M; Palmisano L; Perno C F; Phillips A; Pillay D; Pumarola T; Ruiz L; Salminen M; Schapiro J; Schmidt B; Schmit J C; Schuurman R; Shulse E; Soriano V; Staszewski S; Vella S; Youle M; Ziermann R; Perrin L
Updated European recommendations for the clinical use of HIV drug resistance testing.
Antiviral therapy 2004;9(6):829-48.
2004: Mocroft Amanda; Gatell Jose; Reiss Peter; Ledergerber Bruno; Kirk Ole; Vella Stefano; Blaxhult Anders; Phillips Andrew N; Lundgren Jens;
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
AIDS (London, England) 2004;18(17):2333-7.
2004: Vella Stefano
HIV clinical research in developing countries: challenges and priorities.
Journal of HIV therapy 2004;9(3):49.
2004: Nicastri Emanuele; Sarmati Loredana; d'Ettorre Gabriella; Parisi Saverio G; Palmisano Lucia; Montano Marco; Buonomini Anna Rita; Galluzzo Clementina; Vullo Vincenzo; Concia Ercole; Vella Stefano; Andreoni Massimo
Non-B HIV type 1 subtypes: replicative capacity and response to antiretroviral therapy.
AIDS research and human retroviruses 2004;20(8):816-8.
2004: Panei Pietro; Arcieri Romano; Vella Stefano; Bonati Maurizio; Martini Nello; Zuddas Alessandro
Italian attention-deficit/hyperactivity disorder registry.
Pediatrics 2004;114(2):514.
2004: Yeni Patrick G; Hammer Scott M; Hirsch Martin S; Saag Michael S; Schechter Mauro; Carpenter Charles C J; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2004;292(2):251-65.
2004: Dragsted Ulrik Bak; Mocroft Amanda; Vella Stefano; Viard Jean-Paul; Hansen Ann-Britt E; Panos George; Mercey Danielle; Machala Ladislav; Horban Andrzej; Lundgren Jens D;
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
The Journal of infectious diseases 2004;190(1):148-55.
2004: Reynolds Nancy R; Testa Marcia A; Marc Linda G; Chesney Margaret A; Neidig Judith L; Smith Scott R; Vella Stefano; Robbins Gregory K;
Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study.
AIDS and behavior 2004;8(2):141-50.
2004: d'Arminio Monforte Antonella; Cinque Paola; Mocroft Amanda; Goebel Frank-Detlev; Antunes Francisco; Katlama Christine; Justesen Ulrik Stenz; Vella Stefano; Kirk Ole; Lundgren Jens;
Changing incidence of central nervous system diseases in the EuroSIDA cohort.
Annals of neurology 2004;55(3):320-8.
2004: Grelli Sandro; d'Ettorre Gabriella; Lauria Filippo; Montella Francesco; Di Traglia Loide; Lichtner Miriam; Vullo Vincenzo; Favalli Cartesio; Vella Stefano; Macchi Beatrice; Mastino Antonio
Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients.
The Journal of antimicrobial chemotherapy 2004;53(3):494-500.
2004: d'Ettorre G; Forcina G; Andreotti M; Sarmati L; Palmisano L; Andreoni M; Vella S; Mastroianni C M; Vullo V
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.
Clinical and experimental immunology 2004;135(2):280-5.
2004: Floridia M; Bucciardini R; Fragola V; Galluzzo C M; Giannini G; Pirillo M F; Amici R; Andreotti M; Ricciardulli D; Tomino C; Vella S;
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
HIV medicine 2004;5(1):1-10.
2003: Grelli Sandro; D'Ettore Gabriella; Lauria Filippo; Montella Francesca; Di Traglia Loide; D'Agostini Cartesio; Lichtner Miriam; Vullo Vincenzo; Favalli Cartesio; Vella Stefano; Macchi Beatrice; Mastino Antonio
CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis.
Annals of the New York Academy of Sciences 2003;1010():560-4.
2003: Shafer Robert W; Smeaton Laura M; Robbins Gregory K; De Gruttola Victor; Snyder Sally W; D'Aquila Richard T; Johnson Victoria A; Morse Gene D; Nokta Mostafa A; Martinez Ana I; Gripshover Barbara M; Kaul Pamposh; Haubrich Richard; Swingle Mary; McCarty S Debra; Vella Stefano; Hirsch Martin S; Merigan Thomas C;
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
The New England journal of medicine 2003;349(24):2304-15.
2003: Robbins Gregory K; De Gruttola Victor; Shafer Robert W; Smeaton Laura M; Snyder Sally W; Pettinelli Carla; Dubé Michael P; Fischl Margaret A; Pollard Richard B; Delapenha Robert; Gedeon Linda; van der Horst Charles; Murphy Robert L; Becker Mark I; D'Aquila Richard T; Vella Stefano; Merigan Thomas C; Hirsch Martin S;
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
The New England journal of medicine 2003;349(24):2293-303.
2003: Vella Stefano
Future treatment perspectives.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S95-100.
2003: Fischl Margaret A; Ribaudo Heather J; Collier Ann C; Erice Alejo; Giuliano Marina; Dehlinger Marjorie; Eron Joseph J; Saag Michael S; Hammer Scott M; Vella Stefano; Morse Gene D; Feinberg Judith E; Demeter Lisa M; Eshleman Susan H;
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
The Journal of infectious diseases 2003;188(5):625-34.
2003: Florence E; Lundgren J; Dreezen C; Fisher M; Kirk O; Blaxhult A; Panos G; Katlama C; Vella S; Phillips A;
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.
HIV medicine 2003;4(3):255-62.
2003: Di Fabio Simonetta; Van Roey Jens; Giannini Giacomo; van den Mooter Guy; Spada Massimo; Binelli Andrea; Pirillo Maria F; Germinario Elena; Belardelli Filippo; de Bethune Marie-Pierre; Vella Stefano
Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation.
AIDS (London, England) 2003;17(11):1597-604.
2003: Nicastri Emanuele; Sarmati Loredana; d'Ettorre Gabriella; Parisi Saverio G; Palmisano Lucia; Galluzzo Clementina; Montano Marco; Uccella Ilaria; Amici Roberta; Gatti Francesca; Vullo Vincenzo; Concia Ercole; Vella Stefano; Andreoni Massimo
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.
Journal of clinical microbiology 2003;41(7):3007-12.
2003: Giuliano Marina; Palmisano Lucia; Galluzzo Clementina M; Amici Roberta; Germinario Elena; Okong Pius; Kituuka Praxedes; Mmirro Francis; Magoni Michele; Vella Stefano
Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission.
AIDS (London, England) 2003;17(10):1570-2.
2003: Matarrese Paola; Gambardella Lucrezia; Cassone Antonio; Vella Stefano; Cauda Roberto; Malorni Walter
Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(12):6006-15.
2003: Vella Stefano; Palmisano Lucia
Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
Journal of HIV therapy 2003;8(2):27-8.
2003: Cozzi-Lepri Alessandro; Phillips Andrew N; Miller Veronica; Katlama Christine; Ledergerber Bruno; Vella Stefano; Weber Jonathan; Bruun Johan N; Kirk Ole; Clotet Bonaventura; Lundgrens Jens D
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2003: Sarmati Loredana; Nicastri Emanuele; Uccella Ilaria; D'Ettorre Gabriella; Parisi Saverio G; Palmisano Lucia; Galluzzo Clementina; Concia Ercole; Vullo Vincenzo; Vella Stefano; Andreoni Massimo
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.
Journal of clinical microbiology 2003;41(4):1760-2.
2003: Nicastri Emanuele; Sarmati Loredana; d'Ettorre Gabriella; Palmisano Lucia; Parisi Saverio G; Uccella Ilaria; Rianda Alessia; Concia Ercole; Vullo Vincenzo; Vella Stefano; Andreoni Massimo
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Journal of medical virology 2003;69(1):1-6.
2002: Marazzi Maria Cristina; Palombi Leonardo; Emberti Gialloreti Leonardo; Guidotti Giovanni; Liotta Giuseppe; Perno Federico; Vella Stefano; Narciso Pasquale
[DREAM project early results (drug resources enhancement against AIDS in Mozambique)]
Igiene e sanità pubblica 2002;58(6):431-40.
2002: Hogg Robert; Cahn Pedro; Katabira Elly T; Lange Joep; Samuel N M; O'Shaughnessy Michael; Vella Stefano; Wainberg Mark A; Montaner Julio
Time to act: global apathy towards HIV/AIDS is a crime against humanity.
Lancet 2002;360(9347):1710-1.
2002: D'Ettorre Gabriella; Forcina Gabriele; Andreotti Mauro; Sarmati Loredana; Palmisano Lucia; Galluzzo Clementina M; Nicastri Emanuele; Mastroianni Claudio M; Vullo Vincenzo; Vella Stefano; Andreoni Massimo
Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production.
AIDS (London, England) 2002;16(14):1877-85.
2002: Vella Stefano
Antiretroviral drug resistance and HIV/AIDS in the developing world.
Journal of HIV therapy 2002;7(3):53-5.
2002: Lucia Mothanje Barbara; Rutella Sergio; Leone Giuseppe; Larocca Luigi Maria; Vella Stefano; Cauda Roberto
In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
Journal of acquired immune deficiency syndromes (1999) 2002;30(4):369-78.
2002: Havlir Diane; Vella Stefano; Hammer Scott
The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society.
AIDS (London, England) 2002;16(10):7-9.
2002: Miller Veronica; Phillips Andrew N; Clotet Bonaventura; Mocroft Amanda; Ledergerber Bruno; Kirk Ole; Ormaasen Vidar; Gargalianos-Kakolyris Panagiotis; Vella Stefano; Lundgren Jens D
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
The Journal of infectious diseases 2002;186(2):189-97.
2002: Yeni Patrick G; Hammer Scott M; Carpenter Charles C J; Cooper David A; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Hirsch Martin S; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Saag Michael S; Schechter Mauro; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2002;288(2):222-35.
2002: Floridia M; Fragola V; Galluzzo C M; Giannini G; Pirillo M F; Andreotti M; Tomino C; Vella S
HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial.
HIV medicine 2002;3(2):75-84.
2002: Vella Stefano
Access to HIV care and treatment in the developing world: responding to the objections.
AIDS clinical care 2002;14(3):19-21, 23, 26.
2001: Di Fabio S; Giannini G; Lapenta C; Spada M; Binelli A; Germinario E; Sestili P; Belardelli F; Proietti E; Vella S
Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides.
AIDS (London, England) 2001;15(17):2231-8.
2001: Viganò A; Pinti M; Nasi M; Moretti L; Balli F; Mussini C; Bricalli D; Sala N; Bugarini R; Vella S; Principi N; Cossarizza A
Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age.
The Journal of allergy and clinical immunology 2001;108(3):439-45.
2001: Vella S; Palmisano L
Facing an emerging threat: the spread of HIV resistance.
Journal of HIV therapy 2001;6(3):49-50.
2001: Lucia M B; Rutella S; Leone G; Vella S; Cauda R
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):321-30.
2001: Hale P; Makgoba M W; Merson M H; Quinn T C; Richman D D; Vella S; Wabwire-Mangen F; Wain-Hobson S; Weiss R A
Success hinges on support for treatment.
Nature 2001;412(6844):272.
2001: Hale P; Makgoba M W; Merson M H; Quinn T C; Richman D D; Vella S; Wabwire-Mangen F; Wain-Hobson S; Weiss R A
Mission now possible for AIDS fund.
Nature 2001;412(6844):271-2.
2001: Conway B; Wainberg M A; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange J M; Montaner J S
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
AIDS (London, England) 2001;15(10):1269-74.
2001: Grelli S; Di Traglia L; Matteucci C; Lichtner M; Vullo V; Di Sora F; Lauria F; Montella F; Favalli C; Vella S; Macchi B; Mastino A
Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression.
AIDS (London, England) 2001;15(9):1178-81.
2001: Veldkamp A I; Weverling G J; Lange J M; Montaner J S; Reiss P; Cooper D A; Vella S; Hall D; Beijnen J H; Hoetelmans R M
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Kallings L O; Vella S
Access to HIV/AIDS care and treatment in the south of the world.
AIDS (London, England) 2001;15(7):IAS1-3.
2001: Matarrese P; Testa U; Cauda R; Vella S; Gambardella L; Malorni W
Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis.
The Biochemical journal 2001;355(Pt 3):587-95.
2000: Floridia M; Tomino C; Bucciardini R; Ricciardulli D; Fragola V; Pirillo M F; Amici R; Giannini G; Galluzzo C M; Andreotti M; Seeber A C; Ammassari A; Cingolani A; Lazzarin A; Scalise G; Cargnel A; Suter F; Milazzo F; Pastore G; Moroni M; Ciammarughi R; Pini R; Carosi G; D'Amato C; Contu L; Concia E; Bonazzi L; Aiuti F; Vigevani G; Vella S;
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
AIDS research and human retroviruses 2000;16(17):1809-20.
2000: Bucciardini R; Wu A W; Floridia M; Fragola V; Ricciardulli D; Tomino C; Weimer L E; Pirillo M F; Mirra M; Marzi M; Giannini G; Galluzzo C M; Andreotti M; Massella M; Vella S;
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
AIDS (London, England) 2000;14(16):2567-74.
2000: Floridia M; Massella M; Bucciardini R; Perucci C A; Rossi L; Tomino C; Fragola V; Ricciardulli D; Galluzzo C M; Giannini G; Pirillo M F; Andreotti M; Mirra M; Vella S
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
HIV clinical trials 2000;1(2):9-16.
2000: Benagiano G; Rezza G; Vella S
Condom use for preventing the spread of HIV/AIDS: an ethical imperative.
Journal of the Royal Society of Medicine 2000;93(9):453-6.
2000: Vella S; Galluzzo M C; Giannini G; Pirillo M F; Andreotti M; Tomino C; Fragola V; Bucciardini R; Ricciardulli D; Binelli A; Weimer L E; Floridia M
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
Antiviral research 2000;47(3):189-98.
2000: Van Vaerenbergh K; Van Laethem K; Albert J; Boucher C A; Clotet B; Floridia M; Gerstoft J; Hejdeman B; Nielsen C; Pannecouque C; Perrin L; Pirillo M F; Ruiz L; Schmit J C; Schneider F; Schoolmeester A; Schuurman R; Stellbrink H J; Stuyver L; Van Lunzen J; Van Remoortel B; Van Wijngaerden E; Vella S; Witvrouw M; Yerly S; De Clercq E; Destmyer J; Vandamme A M
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
Antimicrobial agents and chemotherapy 2000;44(8):2109-17.
2000: Vella S
Structured treatment interruptions and treatment intensification.
AIDS clinical care 2000;12(7):55-7, 62.
2000: Grelli S; Campagna S; Lichtner M; Ricci G; Vella S; Vullo V; Montella F; Di Fabio S; Favalli C; Mastino A; Macchi B
Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy.
AIDS (London, England) 2000;14(8):939-49.
2000: Hirsch M S; Brun-Vézinet F; D'Aquila R T; Hammer S M; Johnson V A; Kuritzkes D R; Loveday C; Mellors J W; Clotet B; Conway B; Demeter L M; Vella S; Jacobsen D M; Richman D D
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(18):2417-26.
2000: Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
AIDS (London, England) 2000;14(4):345-55.
2000: Gatti G; Vigano' A; Sala N; Vella S; Bassetti M; Bassetti D; Principi N
Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Antimicrobial agents and chemotherapy 2000;44(3):752-5.
2000: Vella S; Palmisano L
HIV eradication revisited.
Expert opinion on investigational drugs 2000;9(2):193-7.
2000: Vigano A; Vella S; Saresella M; Vanzulli A; Bricalli D; Di Fabio S; Ferrante P; Andreotti M; Pirillo M; Dally L G; Clerici M; Principi N
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
AIDS (London, England) 2000;14(3):251-61.
2000: Vella S; Palmisano L
Antiretroviral therapy: state of the HAART.
Antiviral research 2000;45(1):1-7.
2000: Vella S; Palmisano L
HIV therapy in the post-eradication era.
Journal of biological regulators and homeostatic agents 2000;14(1):34-7.
2000: Carpenter C C; Cooper D A; Fischl M A; Gatell J M; Gazzard B G; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schechter M; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(3):381-90.
1999: Viganò A; Dally L; Bricalli D; Sala N; Pirillo M; Saresella M; Trabattoni D; Vella S; Clerici M; Principi N
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.
The Journal of pediatrics 1999;135(6):675-82.
1999: Raboud J M; Rae S; Vella S; Harrigan P R; Bucciardini R; Fragola V; Ricciardulli D; Montaner J S
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Journal of acquired immune deficiency syndromes (1999) 1999;22(3):260-6.
1999: Gatti G; Di Biagio A; Casazza R; De Pascalis C; Bassetti M; Cruciani M; Vella S; Bassetti D
The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring.
AIDS (London, England) 1999;13(15):2083-9.
1999: Lyles C M; Dorrucci M; Vlahov D; Pezzotti P; Angarano G; Sinicco A; Alberici F; Alcorn T M; Vella S; Rezza G
Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load.
The Journal of infectious diseases 1999;180(4):1018-24.
1999: Craven D; Vella S
A case for proactive switching?
AIDS clinical care 1999;11(8):66-7.
1999: Dragoni F; Cafolla A; Gentile G; Mazzucconi M G; Vella S; Di Corpo U; Tosti M E; Pisani G; Donato V; Martino P
HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy.
Haematologica 1999;84(6):525-9.
1999: Vigano' A; Vella S; Principi N; Bricalli D; Sala N; Salvaggio A; Saresella M; Vanzulli A; Clerici M
Thymus volume correlates with the progression of vertical HIV infection.
AIDS (London, England) 1999;13(5):F29-34.
1999: Floridia M; Bucciardini R; Ricciardulli D; Fragola V; Pirillo M F; Weimer L E; Tomino C; Giannini G; Galluzzo C M; Andreotti M; Cargnel A; Alberici F; De Rienzo B; Leoncini F; Fiaccadori F; Francisci D; Grillone W; Ortona L; Piazza M; Scalzini A; Nigra E; Tumietto F; Vella S
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(1):11-9.
1999: Yarchoan R; Vella S
AIDS 1999. Clinical treatment: overview.
AIDS (London, England) 1999;13 Suppl A():S175-6.
1998: Andreoni M; Sarmati L; Nicastri E; Ventura L; Ercoli L; Parisi S G; Giannini G; Galluzzo C; Vella S
Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy.
Journal of medical virology 1998;56(4):332-6.
1998: Mocroft A; Vella S; Benfield T L; Chiesi A; Miller V; Gargalianos P; d'Arminio Monforte A; Yust I; Bruun J N; Phillips A N; Lundgren J D
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
Lancet 1998;352(9142):1725-30.
1998: Rae S; Raboud J M; Conway B; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg M A; Robinson P; Myers M; Hall D; Montaner J S
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
AIDS (London, England) 1998;12(16):2185-92.
1998: Montaner J S; Raboud J; Rae S; Vella S
British HIV Association guidelines.
Lancet 1998;352(9135):1226-7.
1998: Raboud J M; Montaner J S; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg M A; Robinson P; Myers M; Hall D
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
AIDS (London, England) 1998;12(13):1619-24.
1998: Vella S
HIV treatment--a rational approach to the use of antiretroviral agents.
Haemophilia : the official journal of the World Federation of Hemophilia 1998;4(4):616-8.
1998: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 1998;280(1):78-86.
1998: Hirsch M S; Conway B; D'Aquila R T; Johnson V A; Brun-Vézinet F; Clotet B; Demeter L M; Hammer S M; Jacobsen D M; Kuritzkes D R; Loveday C; Mellors J W; Vella S; Richman D D
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
JAMA : the journal of the American Medical Association 1998;279(24):1984-91.
1998: Hall D B; Montaner J G; Reiss P; Cooper D; Vella S; Dohnanyi C; Myers M; Lange J; Conway B
Induction-maintenance antiretroviral therapy: proof of concept.
AIDS (London, England) 1998;12(7):F41-4.
1998: Vella S
Advances in the virology of HIV infections and implications for clinical management.
AIDS clinical care 1998;10(3):17-9.
1998: Montaner J S; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg M A; Smith D; Robinson P; Hall D; Myers M; Lange J M
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
JAMA : the journal of the American Medical Association 1998;279(12):930-7.
1998: Pontesilli O; Guerra E C; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber A C; Vella S; Ortona L; Aiuti F
Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
AIDS (London, England) 1998;12(5):473-80.
1998: Vella S; Floridia M
Saquinavir. Clinical pharmacology and efficacy.
Clinical pharmacokinetics 1998;34(3):189-201.
1998: Phillips A N; Katlama C; Barton S; Vella S; Blaxhult A; Clotet B; Goebel F D; Hirschel B; Pedersen C; Lundgren J D
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(3):239-44.
1998: Napoli P A; Dorrucci M; Serraino D; Pezzotti P; Franceschi S; Vella S; Rezza G
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.
European journal of epidemiology 1998;14(1):41-7.
1998: de Jong M D; Boucher C A; Danner S A; Gazzard B; Griffiths P D; Katlama C; Lange J M; Richman D D; Vella S
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections.
Antiviral research 1998;37(1):1-16.
1998: Vella S; Mildvan D
AIDS 1998. Clinical treatment: overview.
AIDS (London, England) 1998;12 Suppl A():S147-8.
1997: Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
Journal of medical virology 1997;53(4):313-8.
1997: Lundgren J D; Phillips A N; Vella S; Katlama C; Ledergerber B; Johnson A M; Reiss P; Gatell J; Clumeck N; Dietrich M; Benfield T L; Nielsen J O; Pedersen C
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(3):153-60.
1997: Ercoli L; Sarmati L; Nicastri E; Giannini G; Galluzzo C; Vella S; Andreoni M
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity.
AIDS (London, England) 1997;11(10):1211-7.
1997: Vella S
Clinical implications of resistance to antiretroviral drugs.
AIDS clinical care 1997;9(6):45-7, 49, 52.
1997: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 1997;277(24):1962-9.
1997: Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo M F; Vella S
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
AIDS research and human retroviruses 1997;13(7):555-61.
1997: Mocroft A J; Lundgren J D; d'Armino Monforte A; Ledergerber B; Barton S E; Vella S; Katlama C; Gerstoft J; Pedersen C; Phillips A N
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.
International journal of epidemiology 1997;26(2):400-7.
1997: de Jong M D; Vella S; Carr A; Boucher C A; Imrie A; French M; Hoy J; Sorice S; Pauluzzi S; Chiodo F; Weverling G J; van der Ende M E; Frissen P J; Weigel H M; Kauffmann R H; Lange J M; Yoon R; Moroni M; Hoenderdos E; Leitz G; Cooper D A; Hall D; Reiss P
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1997: Floridia M; Vella S; Seeber A C; Tomino C; Fragola V; Weimer L E; Ricciardulli D; Milazzo F; Gritti F M; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
The Journal of infectious diseases 1997;175(2):255-64.
1997: Vella S; Fragola V; Palmisano L
Recent advances in antiretroviral therapy of HIV infection.
Journal of biological regulators and homeostatic agents 1997;11(1-2):60-3.
1996: Chiesi A; Seeber A C; Dally L G; Floridia M; Rezza G; Vella S
AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-93) and differential incidence according to mode of transmission of HIV-1 infection.
Journal of the neurological sciences 1996;144(1-2):107-13.
1996: Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Antiviral therapy 1996;1(3):129-40.
1996: Sudre P; Hirschel B J; Gatell J M; Schwander S; Vella S; Katlama C; Ledergerber B; d'Arminio Monforte A; Goebel F D; Pehrson P O; Pedersen C; Lundgren J D
Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group.
Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1996;77(4):322-8.
1996: Vella S; Floridia M; Dally L G; Tomino C; Fragola V; Weimer L E; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(5):462-9.
1996: Hermans P; Lundgren J; Sommereijns B; Pedersen C; Vella S; Katlama C; Lüthy R; Pinching A J; Gerstoft J; Pehrson P; Clumeck N
Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.
AIDS (London, England) 1996;10(8):911-7.
1996: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Sáag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
JAMA : the journal of the American Medical Association 1996;276(2):146-54.
1996: Carr A; Vella S; de Jong M D; Sorice F; Imrie A; Boucher C A; Cooper D A
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
AIDS (London, England) 1996;10(6):635-41.
1996: Jacobsen H; Hänggi M; Ott M; Duncan I B; Owen S; Andreoni M; Vella S; Mous J
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
The Journal of infectious diseases 1996;173(6):1379-87.
1996: Corey L; Hirsch M; Skowron G; Vella S
The use of protease inhibitors. A sampling of opinions. Interview by Deborah J Cotton.
AIDS clinical care 1996;8(5):37-41.
1996: Jacobsen H; Haenggi M; Ott M; Duncan I B; Andreoni M; Vella S; Mous J
Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.
Antiviral research 1996;29(1):95-7.
1996: Vella S; Galluzzo C; Giannini G; Pirillo M F; Duncan I; Jacobsen H; Andreoni M; Sarmati L; Ercoli L
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.
Antiviral research 1996;29(1):91-3.
1996: Chiesi A; Vella S; Dally L G; Pedersen C; Danner S; Johnson A M; Schwander S; Goebel F D; Glauser M; Antunes F
Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(1):39-44.
1996: Vella S; Franca Pirillo M
Combination therapy in the management of HIV infection.
Methods and findings in experimental and clinical pharmacology 1996;18 Suppl C():23-6.
1995: Vella S
Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini.
Journal of the International Association of Physicians in AIDS Care 1995;1(11):12-8.
1995: Vella S
Clinical experience with saquinavir.
AIDS (London, England) 1995;9 Suppl 2():S21-S25.
1995: Vella S
Update on HIV protease inhibitors.
AIDS clinical care 1995;7(10):79-82, 88.
1995: Vella S
Immunological and virological markers in HIV infection.
AIDS clinical care 1995;7(5):37-40.
1995: Vella S; Giuliano M; Floridia M; Chiesi A; Tomino C; Seeber A; Barcherini S; Bucciardini R; Mariotti S
Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients.
AIDS (London, England) 1995;9(1):51-6.
1995: Vella S
Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10 Suppl 1():S58-61.
1995: Vella S
HIV pathogenesis and treatment strategies.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10 Suppl 1():S20-3.
1994: Vella S
HIV therapy advances. Update on a proteinase inhibitor.
AIDS (London, England) 1994;8 Suppl 3():S25-9.
1994: Vella S
Update on antiretroviral therapy of HIV infection.
Journal of biological regulators and homeostatic agents 1994;8(3):71-6.
1994: Lundgren J D; Phillips A N; Pedersen C; Clumeck N; Gatell J M; Johnson A M; Ledergerber B; Vella S; Nielsen J O
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.
JAMA : the journal of the American Medical Association 1994;271(14):1088-92.
1994: Vella S; Floridia M; Chiesi A; Tomino C; Ricciardulli D
Recent advances in antiretroviral therapy of HIV infection.
Rays 1994;19(2):198-207.
1994: Lundgren J D; Pedersen C; Clumeck N; Gatell J M; Johnson A M; Ledergerber B; Vella S; Phillips A; Nielsen J O
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group.
BMJ (Clinical research ed.) 1994;308(6936):1068-73.
1994: Vella S; Chiesi A; Volpi A; Giuliano M; Floridia M; Dally L G; Binkin N
Differential survival of patients with AIDS according to the 1987 and 1993 CDC case definitions.
JAMA : the journal of the American Medical Association 1994;271(15):1197-9.
1994: Sarmati L; Ercoli L; Parisi S G; Rocchi G; Giannini G; Galluzzo C; Vella S; Andreoni M
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment.
Journal of acquired immune deficiency syndromes 1994;7(1):10-4.
1994: Vella S; Giuliano M; Dally L G; Agresti M G; Tomino C; Floridia M; Chiesi A; Fragola V; Moroni M; Piazza M
Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group.
Journal of acquired immune deficiency syndromes 1994;7(1):31-8.
1992: Sieh E; Coluzzi M L; Cusella De Angelis M G; Mezzogiorno A; Floridia M; Canipari R; Cossu G; Vella S
The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study.
AIDS research and human retroviruses 1992;8(5):639-49.
1992: Vella S; Giuliano M; Pezzotti P; Agresti M G; Tomino C; Floridia M; Greco D; Moroni M; Visco G; Milazzo F
Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group.
JAMA : the journal of the American Medical Association 1992;267(9):1232-6.
1990: Vella S; Sarmati L; Milanese G; Rocchi G
[Infectious diseases]
Medicina (Florence, Italy) 1990;10(4):442-5.
1990: Chiesi A; Agresti M G; Dally L G; Zaccarelli M; Tomino C; Floridia M; Vella S
[Decrease in notifications of AIDS dementia complex in 1989-1990 in Italy: possible role of the early treatment with zidovudine]
Medicina (Florence, Italy) 1990;10(4):415-6.
1990: Sarmati L; Vella S; Rocchi G
[Controversies concerning the use of zidovudine in the treatment of asymptomatic HIV+ subjects with a low number of CD4+ lymphocytes]
Medicina (Florence, Italy) 1990;10(2):195-7.
1989: Cossu G; Cusella-De Angelis M G; Senni M I; De Angelis L; Vivarelli E; Vella S; Bouchè M; Boitani C; Molinaro M
Adrenocorticotropin is a specific mitogen for mammalian myogenic cells.
Developmental biology 1989;131(2):331-6.
1988: Donelli G; Ruggeri F M; Tinari A; Marziano M L; Menichella D; Caione D; Concato C; Rocchi G; Vella S
A three-year diagnostic and epidemiological study on viral infantile diarrhoea in Rome.
Epidemiology and infection 1988;100(2):311-20.
1982: DeFreitas E C; Vella S; Linnenbach A; Zmijewski C; Koprowski H; Croce C M
Antigen-specific human T-cell hybridomas with helper activity.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(21):6646-50.
1982: DeFreitas E C; Vella S; Linnenbach A; Croce C M; Koprowski H
Human T cell hybridomas with tetanus-toxoid-specific helper activity.
Current topics in microbiology and immunology 1982;100():191-201.
1981: Rochi G U; Vella S; Resta S; Cochi S; Donelli G; Tangucci F; Menichella D; Varveri A; Inglese R
Outbreak of rotavirus gastroenteritis among premature infants.
British medical journal (Clinical research ed.) 1981;283(6296):886.
1980: Crifö S; Vella S; Filiaci F; Resta S; Rocchi G
Secretory immune response after nasal vaccination with live attenuated influenza viruses.
Rhinology 1980;18(2):87-92.
1980: Vella S; Rocchi G; Resta S; Marcelli M; De Felici A
Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination.
Journal of medical virology 1980;6(3):203-11.
1979: Rocchi G; Ragona G; Piga C; Pelosio A; Volpi A; Vella S; Legniti N; de Felici A
Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease.
The Journal of hygiene 1979;83(3):383-90.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

STEFANO VELLA

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Procedures

Concepts & Ideas

Physiology

Geographic Areas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of STEFANO VELLA (preview)

All Publications